Analysts wary of Zydus Life's US sales post FY25, valuations; stock down 5%

Q: How long will it take to read this news story?

The story "Analysts wary of Zydus Life&#039;s US sales post FY25, valuations; stock down 5%" has 803 words across 29 sentences, which will take approximately 4 - 7 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "Analysts wary of Zydus Life&#039;s US sales post FY25, valuations; stock down 5%" was covered 6 hours ago by Business Standard, a news publisher based in India.

Q: How trustworthy is 'Business Standard' news outlet?

Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news. The outlet is headquartered in India and publishes an average of 206 news stories per day. It's most recent story was published 2 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #22026140</li><li>URL: https://beamstart.com/news/analysts-wary-of-zydus-lifes-17234411203060</li></ul>

Business Standard Logo Business Standard 6h ago

Analysts wary of Zydus Life's US sales post FY25, valuations; stock down 5% - Business Standard

Quick Summary:

Shares of Zydus lifesciences slipped 5.3 per cent to Rs 1232.

The brokerage said that the company’s US sales benefited from Myrbetriq launch while Revlimid continued to dictate overall performance, adding that Myrbetriq would remain the key product for FY25. Myrbetriq is a medication used to treat overactive bladder, while Revlimid is indicated for multiple myeloma.

This came after investors resorted to profit booking on Zydus stock as it reached hit its 52-week high at Rs 1,323.90 on Friday post announcement of its April-June quarterly earnings for the financial year 2024-25 (Q1FY25).